Previous 10 | Next 10 |
2024-02-20 11:20:24 ET More on United Therapeutics Anticompetitive Behavior At United Therapeutics United Therapeutics: Cheap With Litigation Headwinds Liquidia jumps on win in patent case against United Therapeutics (update) The most crowded pharma longs and...
2024-02-15 11:35:43 ET Summary Liquidia Corporation shares rallied over 80% after an appeals court invalidated the patent of rival United Therapeutics, potentially paving the way for approval of its PAH and PH-ILD medication Yutrepia. However, the FDA recently extended the origina...
2024-02-14 19:49:34 ET Summary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing form...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024. United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. E...
2024-02-12 22:49:38 ET Summary Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a s...
2024-02-12 13:00:10 ET Chris Shibutani from Goldman Sachs issued a price target of $215.00 for UTHR on 2024-02-12 11:00:00. The adjusted price target was set to $215.00. At the time of the announcement, UTHR was trading at $214.74. The overall price target consensus is a...
2024-01-25 08:32:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as...
2024-01-25 06:48:59 ET More on Liquidia Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia Gains Edge In PAH Market Following Key Legal Victory Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript Liquidia announces updates...
2024-01-19 08:00:00 ET Summary The healthcare sector is overvalued by 12.5% based on 11-year averages. Nevertheless, the healthcare providers industry shows a good value score. iShares U.S. Healthcare ETF is an unattractive alternative to XLV. We look at 10 healthcare stocks c...
2024-01-18 11:54:11 ET More on S&P 500 Index: The Window For A Significant Stock Market Decline Is Closing Industrial Production December 2023: No Landing = No Fed Rate Cuts Dollar Rally Pauses, But Fuel From Interest Rate Adjustment May Not Be Complete N...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...